不同药物治疗糖尿病合并高血压临床效果分析(1)
[摘要] 目的 探討不同药物治疗糖尿病合并高血压临床效果。 方法 该组研究纳入在该院治疗的80例糖尿病合并高血压患者，入选时间自2018年10月—2019年10月，将其按照随机抽样方法分成两组。两组均给予降糖药物治疗，同时对照组40例给予硝苯地平控释片治疗，研究组40例给予硝苯地平控释片+厄贝沙坦片治疗。比较两组的临床疗效和安全性。 结果 研究组与对照组患者的总有效率分别为95.00%和80.00%，差异有统计学意义(P<0.05)。研究组与对照组患者的不良反应发生率分别为10.00%和7.50%，差异无统计学意义(P>0.05)。对照组与研究组患者的空腹血糖水平、餐后2 h血糖水平分别为(7.63±3.12)、(8.46±1.02)mmol/L和(6.13±2.03)、(7.06±1.01)mmol/L，差异有统计学意义(P<0.05)。结论 在降糖治疗的同时给予糖尿病合并高血压患者硝苯地平控释片联合厄贝沙坦片治疗有助于提高治疗效果，且不良反应少，安全性高，值得在临床推广。
[关键词] 硝苯地平控释片;厄贝沙坦片;糖尿病合并高血压;不良反应;安全性
[中图分类号] R587.2 [文献标识码] A [文章编号] 1672-4062(2020)09(b)-0059-03
Analysis of the Clinical Effects of Different Drugs in the Treatment of Diabetes with Hypertension
YUAN Jian-shun
Department of Pharmacy， Zhangjiagang Aoyang Hospital Co.， Ltd. Zhangjiagang， Jiangsu Province， 215600 China
[Abstract] Objective To explore the clinical effects of different drugs in the treatment of diabetes with hypertension. Methods This group of studies included 80 patients with diabetes and hypertension treated in the hospital. The selection period was from October 2018 to October 2019. They were divided into two groups according to random sampling method. Both groups were treated with hypoglycemic drugs， while 40 patients in the control group were treated with nifedipine controlled-release tablets， and 40 patients in the study group were treated with nifedipine controlled-release tablets+irbesartan tablets. The clinical efficacy and safety of the two groups were compared. Results The total effective rates of the study group and the control group were 95.00% and 80.00%， respectively， and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the study group and the control group were 10.00% and 7.50%， respectively， and the difference was not statistically significant(P>0.05). The fasting blood glucose level and the 2 h postprandial blood glucose level of the sontrol group and the study group were (7.63±3.12)mmol/L， (8.46±1.02)mmol/L and (6.13±2.03)mmol/L， (7.06±1.01)mmol/L， respectively， and the difference was statistically significant(P<0.05). Conclusion The treatment of nifedipine controlled-release tablets combined with irbesartan tablets in patients with diabetes and hypertension at the same time as hypoglycemic therapy can help improve the therapeutic effect， with few adverse reactions and high safety， it is worthy of clinical promotion.
[Key words] Nifedipine controlled-release tablets; Irbesartan tablets; Diabetes with hypertension; Adverse reactions; Safety, 百拇医药(袁建顺)
[关键词] 硝苯地平控释片;厄贝沙坦片;糖尿病合并高血压;不良反应;安全性
[中图分类号] R587.2 [文献标识码] A [文章编号] 1672-4062(2020)09(b)-0059-03
Analysis of the Clinical Effects of Different Drugs in the Treatment of Diabetes with Hypertension
YUAN Jian-shun
Department of Pharmacy， Zhangjiagang Aoyang Hospital Co.， Ltd. Zhangjiagang， Jiangsu Province， 215600 China
[Abstract] Objective To explore the clinical effects of different drugs in the treatment of diabetes with hypertension. Methods This group of studies included 80 patients with diabetes and hypertension treated in the hospital. The selection period was from October 2018 to October 2019. They were divided into two groups according to random sampling method. Both groups were treated with hypoglycemic drugs， while 40 patients in the control group were treated with nifedipine controlled-release tablets， and 40 patients in the study group were treated with nifedipine controlled-release tablets+irbesartan tablets. The clinical efficacy and safety of the two groups were compared. Results The total effective rates of the study group and the control group were 95.00% and 80.00%， respectively， and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the study group and the control group were 10.00% and 7.50%， respectively， and the difference was not statistically significant(P>0.05). The fasting blood glucose level and the 2 h postprandial blood glucose level of the sontrol group and the study group were (7.63±3.12)mmol/L， (8.46±1.02)mmol/L and (6.13±2.03)mmol/L， (7.06±1.01)mmol/L， respectively， and the difference was statistically significant(P<0.05). Conclusion The treatment of nifedipine controlled-release tablets combined with irbesartan tablets in patients with diabetes and hypertension at the same time as hypoglycemic therapy can help improve the therapeutic effect， with few adverse reactions and high safety， it is worthy of clinical promotion.
[Key words] Nifedipine controlled-release tablets; Irbesartan tablets; Diabetes with hypertension; Adverse reactions; Safety, 百拇医药(袁建顺)